Form 8-K · Current report
Microchip Technology 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0000827054
- Accession no.
- 0000827054-26-000037
Summary
Microchip Technology reported first-quarter fiscal 2027 net sales of $1.485 billion, up 38.0% from a year earlier and above the high end of its prior guidance, with GAAP diluted EPS of $0.37 and non-GAAP EPS of $0.76. CEO Steve Sanghi attributed the quarter to improving demand, inventory normalization and higher factory utilization, and guided September-quarter net sales to $1.589–$1.618 billion, up 7–9% sequentially.
Key points
- GAAP net income attributable to common stockholders was $202.0 million versus a $46.4 million loss a year earlier; non-GAAP net income was $438.6 million.
- Inventory days fell to 175 on June 30 from 185 on March 31, and the company reduced net debt by about $170 million during the quarter.
- PCIe Gen6 connectivity design wins doubled sequentially from six to 12 programs.
- The board declared a quarterly common dividend of 45.5 cents per share and a $18.750 per share dividend on its 7.50% Series A Mandatory Convertible Preferred Stock.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition The information pursuant to Item 2.02 in this report on Form 8-K is being furnished as contemplated by General Instruction B(2) to Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. On August 6, 2026, we announced the results of our operations for the first quarter of fiscal year 2027. The complete release is attached to this report as Exhibit 99.1. Item 9.01. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.